Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Cancer Research UK, Department of Health, and the National Institute for Health Research Cancer Research Network.